Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Is BIO-TECHNE Corp (TECH) a Good Stock To Buy?

Page 1 of 2

Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on several financial news websites. However, in this article we will take a look at their collective moves and analyze what the smart money thinks of BIO-TECHNE Corp (NASDAQ:TECH) based on that data.

BIO-TECHNE Corp (NASDAQ:TECH) experienced an increase in activity from smart money investors between July and September, as the number of funds tracked by Insider Monkey long the stock went up by four to 17. At the end of this article we will also compare TECH to other stocks including HollyFrontier Corp (NYSE:HFC), Store Capital Corp (NYSE:STOR), and BOK Financial Corporation (NASDAQ:BOKF) to get a better sense of its popularity.

Follow Bio-Techne Corp
Trade (TECH) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

dna, bio, clone, helix, medical, health, research, cell, gene, microscopic, render, tech, chemistry, molecular, liquid, life, biotechnology, technology, medicine, molecule,

everything possible/Shutterstock.com

Now, let’s go over the latest action encompassing BIO-TECHNE Corp (NASDAQ:TECH).

How have hedgies been trading BIO-TECHNE Corp (NASDAQ:TECH)?

At the end of September, 17 funds tracked by Insider Monkey held long positions in BIO-TECHNE Corp (NASDAQ:TECH), which represents an increase of 31% from one quarter earlier. On the other hand, there were a total of 11 hedge funds with a bullish position in TECH at the beginning of this year. So, let’s examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

HedgeFundSentimentChart

Of the funds tracked by Insider Monkey, Select Equity Group, led by Robert Joseph Caruso, holds the number one position in BIO-TECHNE Corp (NASDAQ:TECH). Select Equity Group has a $253.7 million position in the stock, comprising 2.2% of its 13F portfolio. Coming in second is Chuck Royce’s Royce & Associates holding a $81.2 million position; the fund has 0.5% of its 13F portfolio invested in the stock. Other peers with similar optimism comprise Jim Simons’ Renaissance Technologies, Ken Griffin’s Citadel Investment Group, and Israel Englander’s Millennium Management. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds which is based on the performance of their 13F long positions in non-microcap stocks.

Page 1 of 2